Key facts
- Absentia Labs’s last known valuation is $25.0M (Mar 2026).
- It has raised $500K; the latest was Early Stage VC in Mar 2026.
- Notable investors include LvlUp Ventures, Kastor Capital, Milemark.capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Absentia Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Absentia Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Absentia Labs
Developer of an AI-driven, organism-wide modeling platform designed to improve early-stage drug safety and translational decision-making. The company offers integration of biological, chemical, and assay data to generate mechanistic, organ-specific risk predictions before GLP toxicology studies begin, enabling pharmaceutical and biotech teams to identify liver, cardiac, kidney, and multi-organ liabilities earlier and reduce late-stage failure risk while prioritizing lead candidates across the discovery-to-IND pipeline.
- Sector
- Healthcare
- HQ
- Somerville, MA, United States
- Founded
- 2024
- Employees
- 5
- Website
- absentia.bio/
- Ownership
- Privately Held (backing)
Absentia Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Absentia Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Absentia Labs in its N-PORT filings yet. We sweep new filings monthly.